Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway

Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway

Abstract Background Lung cancer is one of the most common and deadly tumors around the world. Targeted therapy for patients with certain mutations, especially by use of tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR), has provided significant benefit to patients....

Full description

Bibliographic Details
Main Authors: Yong-An Song, Ting Ma, Xue-Yan Zhang, Xiang-Song Cheng, Ayobami-Matthew Olajuyin, Zhi-Fu Sun, Xiao-Ju Zhang
Format: Article
Language:English
Published: BMC 2019-05-01
Series:Cancer Cell International
Subjects:
Apatinib
PC9 cells
Gefitinib-resistance
Cell cycle arrest
VEGF2 pathway
Online Access:http://link.springer.com/article/10.1186/s12935-019-0836-8

Internet

http://link.springer.com/article/10.1186/s12935-019-0836-8

Similar Items